Hiroshi Mitsumoto, MD

Selected peer-reviewed publications (in chronological order).
Articles (162 refereed journal, 34 chapters, and 7 books/supplements)

  • Mitsumoto H, Bradley WG: The wobbler mouse: the murine motor neuron diseases: degeneration and regeneration of the lower motor neuron. Brain 1982; 105:811-834.

  • Mitsumoto H, Aprille JR, Wray SH, et a. Chronic progressive external ophthalmoplegia (CPEO): clinical, morpho­­logic, and biochemical studies. Neurology 1983; 33:452-461.

  • Mitsumoto H, Sliman RJ, Schafer IA, et al. Motor neuron disease and adult hexo­samini­dase-A deficiency in

two families: Evidence for multi­system degeneration. Ann Neurol 1985;17:378-385.

  • Mitsumoto H, Gambetti P: Impaired slow axonal transport in wobbler mouse motor neuron disease. Ann

Neurol 1986;19:64-68.

  • Mitsumoto H, Salgado ED, Negroski D, et al. Amyotrophic lateral sclerosis: Effects of acute intravenous and chronic subcutan­eous administration of thyrotrophin-releasing hormone in con­trolled trials. Neurology 1986;36:152-159.

  • Mitsumoto H, McQuarrie IG, Kurahashi K, Sunohara N: Histometric and functional characteristics in the subclinical system of wobbler mouse motor neuron disease. Brain 1990;113:497-508.

    Mitsumoto H, Kurahashi K, Jacob JM, McQuarrie IG: Retardation of fast axonal transport in wobbler mice. Muscle Nerve 1993;16:542- 547.

  • Mitsumoto H, Schwartzman MJ, Estes ML, et al. Paroxysmal autonomic dysfunction and sudden death in

stiff-man syndrome. J Neurol 1991;238:91-96.

  • Mitsumoto H, Ikeda K, Holmlund TH, et al. The effects of ciliary neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. Ann Neurol 1994;36:142-8.

  • Mitsumoto H, Ikeda K, Klinkosz B, et al. Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF. Science 1994;265:1107-10.

  • The ALS CNTF Treatment Study (ACTS) Phase III Study Group. A double-blind placebo-controlled trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 1996;46:1244-1249.

  • Mitsumoto H, Olney, RK: Drug combination treatment in patients with ALS: current status and future direction. Neurology 1996;47 (Suppl 2):S103-107.

    Mitsumoto H: Riluzole -- What is its impact in our treatment and understanding of amyotrophic lateral sclerosis? (editorial) Ann Pharmacotherapy 1997;31:779-781.
  • BDNF Study Group (PhaseIII). A controlled trial of recombinant methionyl human BDNF in ALS. Neurology1999;52:1427-1433.

  • Mitsumoto H: Patient choices in ALS. Life-sustaining treatment versus palliative care? (Editorial) Neurology 1999;53:248-249.

  • Mitsumoto H (Supplement editors): Advances in Amyotrophic Lateral Sclerosis. Neurology 1996; 47.

  • Mitsumoto H: (section editor): Continuum. Motor Neuron Disease. American Academy of Neurology. Baltimore: Williams & Wilkins, 1997.

    Mitsumoto H, Tsuzaka K: Invited Review. Neurotrophic factors and neuromuscular diseases. Part I and Part II. Muscle Nerve 1999;22:983-999 (I) and 1000-1021 (II).

  • Mitsumoto H, Chad D, Pioro EP: Monograph. Amyotrophic Lateral Sclerosis. Contemporary Neurology Series 49. Philadelphia: F. A. Davis. 1997:1-480.

  • Mitsumoto H. and Munsat TL. Amyotrophic Lateral Sclerosis: Comprehensive Management and Treatment. Demos Publisher, New York, 1994 (1st edition) and 2001 (2nd edition).

  • Mitsumoto H, Klinkosz B, Pioro EP, Tsuzaka K, Ishiyama T, O'Leary RM, Pennica D. The effects of cardiotrophin-1 (CT-1) in a mouse motor neuron disease. Muscle Nerve 2001; 24:769-777.

  • Przedborski S, Mitsumoto H, Rowland LP. Recent advances in amyotrophic lateral sclerosis. Curr Neurol Neurosci Rep 2003;2:70-77.
  • Mitsumoto H, Davidson M, Moore DH, et al. Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction. ALS Other MND 2003; 4:177-185.

  • Kaufmann P, Pullman SL, Shungu DC, et al and Mitsumoto H. Objective Tests for Upper Motor Neuron Involvement in Amyotrophic Lateral Sclerosis (ALS). Neurology 2004;62:1753-1757.

  • Kaufmann P, Levy G, Thompson JLP, DelBene ML, Mitsumoto H. The ALSFRSr predicts survival time in an ALS clinicl population. Neurology 2005;64:38-43.

  • Mitusmoto H, Bromberg M, Johnston W, et al. Promoting excellence in end-of-life care in ALS. ALS and Other MND 2005;6:145-154.
  • Mitsumoto H, Przedborski S, Gordon P (Eds). Amyotrophic Lateral Sclerosis. Current Science and Approaches to Therapy. Taylor & Francis Group, New York, 2005.

  • Mitsumoto H, Hillyer G, Andrews H, et al. Structured interview for genetic and environmental risk factors in ALS and its test-retest reliability evaluation. Amyotroph Lateral Scler 2005 (suppl 1);6:56.

  • Gordon PH, Cheng B, Katz IB, Pinto M, Hays AP, Mitsumoto H, Rowland LP. The natural history of primary lateral sclerosis. Neurology. 2006;66:647-653.

  • Levy G, Kaufmann P, Buchsbaum R,Montes J, Barsdorf A, Arbing A, Battista V, Zhou X, Mitsumoto H, Levin B, Thompson JLP. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology 2006;66:660–663.

  • Rippon GA, Scarmeas N, Gordon PH, Murphy PL, Albert SM, Mitsumoto H, Marder K, Rowland LP, Stern Y. An observational study of cognitive impairment in amyotrophic lateral sclerosis. Arch Neurol. 2006;63:345-52.

  • Gordon PH, Doorish C, Montes J, Mosley RL, Diamond B, MacArthur RB, Weimer LH, Kaufmann P, Hays AP, Rowland LP, Gendelman HE, Przedborski S, Mitsumoto H. Randomized controlled phase II trial of glatiramer acetate in amyotrophic lateral sclerosis. Neurology 2006;66:1117-1119.

  • Mitsumoto H, Floyd A, Tang MX, Kaufmann P, Battista V, Hristova A, Pullman SL. Transcranial magnetic stimulation for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS). Suppl Clin Neurophysiol. 2006;59:327-32.

  • Rabkin JG, Albert SM, Tider T, Del Bene ML, O'Sullivan I, Rowland LP, Mitsumoto H. Predictors and course of elective long-term mechanical ventilation: A prospective study of ALS patients. Amyotroph Lateral Scler. 2006;7:86-95.

  • Kaufmann P, Mitsumoto H; ALSRG Database Task Force Steering Committee; ALSRG Members. ALS Research Group (ALSRG): second meeting, a summary report. Amyotroph Lateral Scler 2006;7:252-5.

  • Montes J, Levy G, Albert S, Kaufmann P, Buchsbaum R, Gordon PH, Mitsumoto H. Development and Evaluation of a Self-Administered Version of the ALSFRS-R. Neurology 2006;67:1294-6.

  • Gordon PH, Mitsumoto H. Symptomatic therapy and palliative aspects of clinical care. In Eisen AA, Shaw PJ (eds). Motor Neuron Disorders and Related Diseases. Handbook of Clinical Neurology. 2007;82:389-424.

  • Mitsumoto H, Uluğ AM, Pullman SL, et al. Quantitative Objective Markers for Upper and Lower Motor Neuron Dysfunction in Amyotrophic Lateral Sclerosis. Neurology 2007;17:1402-1410.

  • Dal Bello-Haas V, Florence JM, Kloos AD, Scheirbecker J, Lopate G, Hayes SM, Pioro EP, Mitsumoto H. A Randomized Controlled Trial of Resistance Exercise in Individuals with ALS. Neurology 2007;68:2003-2007.

  • Mitsumoto H, Rabkin JG. Palliative Care for Patients with Amyotrophic Lateral Sclerosis. “Prepare for the worst and hope for the best.” JAMA 2007;298: 207-216.

  • Dunckley T, Huentelman MJ, Craig DW, Pearson JV, Szelinger S, Joshipura K, Halperin RF, Stamper C, Jensen KR, Letizia D, Hesterlee SE, Pestronk A, Levine T, Bertorini T, Graves MC, Mozaffar T, Jackson CE, Bosch P, McVey A, Dick A, Barohn R, Lomen-Hoerth C, Rosenfeld J, O'connor DT, Zhang K, Crook R, Ryberg H, Hutton M, Katz J, Simpson EP, Mitsumoto H, Bowser R, Miller RG, Appel SH, Stephan DA. Whole-genome analysis of sporadic amyotrophic lateral sclerosis. N Engl J Med 2007;357:775-88.

  • Gwinn K, Corriveau RA, Mitsumoto H, et al. Amyotrophic Lateral Sclerosis: An Emerging Era of Collaborative Gene Discovery. PloS ONE 2007;2:e1254..